In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 10071-38-2, name is 6-Chloro-2-methylpyridazin-3(2H)-one, introducing its new discovery. name: 6-Chloro-2-methylpyridazin-3(2H)-one
Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 10071-38-2, and how the biochemistry of the body works.name: 6-Chloro-2-methylpyridazin-3(2H)-one
Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N1117 – PubChem